Annual Cash & Cash Equivalents
$2.77 M
-$2.20 M-44.30%
December 1, 2023
Summary
- As of February 7, 2025, RNAZ annual cash & cash equivalents is $2.77 million, with the most recent change of -$2.20 million (-44.30%) on December 1, 2023.
- During the last 3 years, RNAZ annual cash & cash equivalents has risen by +$1.94 million (+234.25%).
- RNAZ annual cash & cash equivalents is now -86.71% below its all-time high of $20.83 million, reached on December 31, 2021.
Performance
RNAZ Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.88 M
-$1.48 M-44.08%
September 1, 2024
Summary
- As of February 7, 2025, RNAZ quarterly cash and cash equivalents is $1.88 million, with the most recent change of -$1.48 million (-44.08%) on September 1, 2024.
- Over the past year, RNAZ quarterly cash and cash equivalents has dropped by -$5.58 million (-74.83%).
- RNAZ quarterly cash and cash equivalents is now -91.66% below its all-time high of $22.50 million, reached on September 30, 2021.
Performance
RNAZ Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RNAZ Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -44.3% | -74.8% |
3 y3 years | +234.3% | -91.7% |
5 y5 years | +1253.3% | - |
RNAZ Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -86.7% | at low | -91.0% | +15.6% |
5 y | 5-year | -86.7% | +1253.3% | -91.7% | +2256.7% |
alltime | all time | -86.7% | +1253.3% | -91.7% | +2256.7% |
TransCode Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $1.88 M(-44.1%) |
Jun 2024 | - | $3.35 M(-31.7%) |
Mar 2024 | - | $4.91 M(+77.5%) |
Dec 2023 | $2.77 M(-44.3%) | $2.77 M(-62.9%) |
Sep 2023 | - | $7.45 M(+108.6%) |
Jun 2023 | - | $3.57 M(+120.2%) |
Mar 2023 | - | $1.62 M(-67.3%) |
Dec 2022 | $4.97 M | $4.97 M(-43.5%) |
Sep 2022 | - | $8.79 M(-34.6%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2022 | - | $13.44 M(-20.3%) |
Mar 2022 | - | $16.85 M(-19.1%) |
Dec 2021 | $20.83 M(+2415.2%) | $20.83 M(-7.4%) |
Sep 2021 | - | $22.50 M(>+9900.0%) |
Jun 2021 | - | $79.60 K(-19.6%) |
Mar 2021 | - | $99.00 K(-88.0%) |
Dec 2020 | $828.00 K(+304.9%) | - |
Dec 2020 | - | $828.00 K |
Dec 2019 | $204.50 K | - |
FAQ
- What is TransCode Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for TransCode Therapeutics?
- What is TransCode Therapeutics annual cash & cash equivalents year-on-year change?
- What is TransCode Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly cash and cash equivalents year-on-year change?
What is TransCode Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RNAZ is $2.77 M
What is the all time high annual cash & cash equivalents for TransCode Therapeutics?
TransCode Therapeutics all-time high annual cash & cash equivalents is $20.83 M
What is TransCode Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, RNAZ annual cash & cash equivalents has changed by -$2.20 M (-44.30%)
What is TransCode Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RNAZ is $1.88 M
What is the all time high quarterly cash and cash equivalents for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly cash and cash equivalents is $22.50 M
What is TransCode Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RNAZ quarterly cash and cash equivalents has changed by -$5.58 M (-74.83%)